NASDAQ Companies - Bay Street News

NASDAQ Companies - September 16, 2024

Checkpoint Therapeutics Announces Cosibelimab Longer-Term Results in Advanced Cutaneous Squamous Cell Carcinoma Presented at ESMO Congress 2024

WALTHAM, Mass., Sept. 16, 2024 (GLOBE NEWSWIRE) — Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology […]

NASDAQ Companies - September 16, 2024

Haleon Selects PubMatic as Supply Optimisation Partner to Enable More Effective, Sustainable Media Buying

LONDON, Sept. 16, 2024 (GLOBE NEWSWIRE) — PubMatic (NASDAQ:PUBM), an independent technology company delivering digital advertising’s supply chain of the […]

NASDAQ Companies - September 16, 2024

Adagene Presents Results at ESMO Congress that Show Best-in-Class Therapeutic Potential for Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) in Combination with KEYTRUDA® (Pembrolizumab) in Advanced/Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC)

– Confirmed partial responses (PRs) doubled to four since ASCO GI in MSS CRC patients without liver and peritoneal metastases […]

NASDAQ Companies - September 16, 2024

MaxCyte Signs Strategic Platform License with Kamau Therapeutics to Accelerate the Development of Cell Therapies for Genetic Diseases

ROCKVILLE, Md. and SOUTH SAN FRANCISCO, Calif., Sept. 15, 2024 (GLOBE NEWSWIRE) — MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a […]

NASDAQ Companies - September 15, 2024

Vera Bradley Foundation for Breast Cancer Raises $1,601,830 for Breast Cancer Research

FORT WAYNE, Ind., Sept. 15, 2024 (GLOBE NEWSWIRE) — The Vera Bradley Foundation for Breast Cancer (the “Foundation”) today announced […]

NASDAQ Companies - September 15, 2024

Replimune Presents Primary Analysis Data from IGNYTE Clinical Trial of RP1 Combined with Nivolumab in Anti-PD1 Failed Melanoma at European Society for Medical Oncology (ESMO) Congress 2024

Data from the IGNYTE primary analysis shows clinically meaningful activity across all subgroups, including those who had received prior anti-PD1 […]

NASDAQ Companies - September 15, 2024

23andMe Therapeutics Announces Phase 2 Results for Two Additional Cancer Cohorts and Correlative Biomarker Data from 23ME-00610 Study

23ME-00610 monotherapy demonstrates preliminary evidence of clinical benefit in clear-cell renal-cell carcinoma, with one confirmed partial response Higher tumor expression […]